BioLight announced the completion of a U.S. clinical study, conducted by Ora, Inc. Andover, MA, designed to compare widelyused benchmark tests for dry eye with its TeaRx™ diagnostic parameters that test components of tear film. Positive statistical correlations were identified between TeaRx™ diagnostic parameters and widely used benchmark tests for dry …
BioLightannounces the Israel patent office has issued patent covering the core of the IOPtiMate™ Technology for a non-penetrating laser assisted filtration surgery technology for treating glaucoma.
BioLight announced its investment in a newly-formed ophthalmic company that has licensed-in a world-wide drug-delivery platform from the Hebrew University, Israel, that has the potential to enable more efficient and safer delivery of eye drops.
BioLight announced that its IOPtima subsidiary has signed an exclusive distribution agreement for the sale and marketing of the IOPtiMateTM system in Hong Kong and Macao, including the purchase of at least 9 systems during the initial term of the agreement.
BioLight announces the first sale of an IOPtiMate™ system to a medical center located in Poland following a successful product trial.
BioLight announced that Suzana Nahum-Zilberberg, CEO, and Itai Bar Natan, CFO, will present at the Canaccord Genuity Medical Technology and Diagnostics Forum at the Westin Grand Central in New York, NY.
BioLight announced that Ronen Castro, CEO of its subsidiary IOPtima Ltd., will present at the OIS@AAO (Ophthalmology Innovation Summit @ the American Academy of Ophthalmology) on Thursday, October 16, 2014, at 10:55 a.m. at the Palmer House Hilton in Chicago, IL.
BioLight announces the first sale of an IOPtiMate™ system in Hong Kong.
A medical center in Hong Kong purchased the IOPtiMate™ system following a successful trial, and an additional IOPtiMate™ system has been installed on a trial basis at a second medical center in Hong Kong.
BioLight announces the U.S. Patent and Trademark Office has issued patent number 8,765,166 covering the device that is inserted into the eye to treat an ocular condition that contains an active agent of a free acid salt form of a prostaglandin with a low elution rate profile that is contained in …
BioLight announced today that Micromedic Technologies (TASE: MCTC), BioLight’s cancer diagnostic cluster company, achieved successful interim results in a blinded bladder cancer clinical trial with its CellDetect® technology. As a result, Micromedic will continue the trial with the goal of developing a kit for monitoring the recurrence of bladder cancer. This …